Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection.


Journal

Le infezioni in medicina
ISSN: 2532-8689
Titre abrégé: Infez Med
Pays: Italy
ID NLM: 9613961

Informations de publication

Date de publication:
01 Nov 2020
Historique:
entrez: 1 12 2020
pubmed: 2 12 2020
medline: 31 8 2021
Statut: ppublish

Résumé

Single nucleotide polymorphisms (SNPs) in the interleukin 28B (IL28B) gene can influence the course of treated and untreated HBV infection. However, the correlation between different IL28B-SNPs and HBVDNA and quantitative HBsAg (qHBsAg) in chronic HBV infection remains to be fully elucidated. Patients with chronic HBV infection were analysed for qHBsAg, HBVDNA, HBV genotype and six IL28B-SNPs (rs12980275, rs8105790, rs8099917, rs7248668, rs12979860, rs10853728). Seventy patients were recruited: 80% Caucasian, 56% genotype D, 44% treated with nucleos(t)ide analogues, 11% cirrhotic, 37% inactive carriers (IC). Median (IQR) qHBsAg and HBVDNA were 3.2 log10 IU/ml (2.2-3.9) and 2.2 log10 IU/ml (0.3-3.3), respectively. Lower levels of qHBsAg were associated in the whole study population with rs12979860 CC vs. CT (p=0.05), rs12980275 AA vs. AG (p=0.04), rs8105790 TT vs. CT (p=0.05) and genotype D vs. A+E (p=0.01). rs8105790 TT was present in 81% of IC vs. 46% non-IC (p=0.005). These data were also confirmed in the untreated patients' subgroup. In multivariate analysis, IL28B-SNP haplogroups were associated with lower qHBsAg: CC/AA at rs12979860/rs12980275 (-0.70 log IU/mL, 95% CI -1.26;-0.14; p=0.01), CC/TT at rs12979860/rs8105790 (-0.78 log IU/mL, 95% CI -1.33;-0.23; p=0.006) and AA/TT at rs12980275/rs8105790 (-0.71 log IU/mL, 95% CI -1.27;-0.17; p=0.01) both in the whole population and in the untreated subgroup. Specific IL28-SNP haplogroups might be associated with lower qHBsAg.

Identifiants

pubmed: 33257634

Substances chimiques

Hepatitis B Surface Antigens 0
interferon-lambda, human 0
Interferons 9008-11-1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

576-586

Auteurs

Alessandra Vergori (A)

Department of Medical Biotechnology, University of Siena, Siena, Italy; University Infectious Diseases Unit, Siena University Hospital, Siena, Italy; HIV/AIDS Department, National Institute for Infectious Diseases, IRCCS, L. Spallanzani, Rome, Italy.

Barbara Rossetti (B)

University Infectious Diseases Unit, Siena University Hospital, Siena, Italy.

Ilaria Vicenti (I)

Department of Medical Biotechnology, University of Siena, Siena, Italy.

Genny Meini (G)

Department of Medical Biotechnology, University of Siena, Siena, Italy.

Gianluca Lentini (G)

Microbiology and Virology Unit, Siena University Hospital, Siena, Italy.

Beatrice Valoriani (B)

University Infectious Diseases Unit, Siena University Hospital, Siena, Italy.

Cinzia Caudai (C)

Microbiology and Virology Unit, Siena University Hospital, Siena, Italy.

Matteo Morandi (M)

Department of Medical Biotechnology, University of Siena, Siena, Italy.

Maria Grazia Cusi (MG)

Microbiology and Virology Unit, Siena University Hospital, Siena, Italy.

Maurizio Zazzi (M)

Department of Medical Biotechnology, University of Siena, Siena, Italy; Department of Molecular Biology, University of Siena, Siena, Italy.

Andrea De Luca (A)

Department of Medical Biotechnology, University of Siena, Siena, Italy; University Infectious Diseases Unit, Siena University Hospital, Siena, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH